Drug intelligence / Profile preview

ursodeoxycholic acid + placebo

Development stage
Unknown
Lead developer
Daewoong Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

"Ursa tab. 200mg & CnU placebo cap. 250mg" is a co-administration regimen consisting of the active drug Ursa (ursodeoxycholic acid, 200 mg) and a matching placebo capsule (250 mg) for the investigational drug CnU. This regimen is used as the active comparator arm in a Phase 4 clinical trial (NCT07005752; MMP-401) sponsored by Myungmoon Pharm to evaluate the efficacy and safety of CnU (a combination of chenodeoxycholic acid and ursodeoxycholic acid) in patients with cholesterol cholelithiasis (radiolucent cholesterol gallstones). Ursodeoxycholic acid is a naturally occurring hydrophilic bile acid that acts as a litholytic agent by reducing biliary cholesterol saturation, thereby promoting the dissolution of cholesterol gallstones.

Other names
UDCA + placeboUrsa + placeboUrsa tab. 200mg & CnU placebo cap. 250mgursodeoxycholic acid + placebo
02

Targets

AKR1C2 (Aldo-keto reductase family 1 member C2)BLVRA (Biliverdin reductase A)GPBAR1FXR (Farnesoid x-activated receptor)SLC23A2 (Sodium-dependent vitamin C transporter 2)BAR (Bile acid receptor)

Beyond the preview

Go deeper on ursodeoxycholic acid + placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ursodeoxycholic acid + placebo.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call